ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Economics"

  • Abstract Number: 1286 • ACR Convergence 2022

    Increasing Biosimilar Uptake in the Rheumatology Clinics Within a Large Academic Medical Center

    Joad Eseddi1, DeAnne Carmichael2, Shannon Wishin3 and Puneet Bajaj2, 1UT Southwestern School of Medicine, Dallas, TX, 2UT Southwestern Medical Center, Dallas, TX, 3UT Southwestern Medical Centre, Dallas, TX

    Background/Purpose: Biological drugs have revolutionized the treatment of rheumatic diseases. However, increasing the use of biologics over the past few years has directly contributed towards…
  • Abstract Number: 1312 • ACR Convergence 2022

    Cost-Effectiveness of Sequential Treatment with Abaloparatide Followed by Alendronate in US Men at High Risk of Fracture

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Leny Pearman4, jake Mathew4, Yamei Wang4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedar-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Waltham, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Previous cost-effectiveness analyses in postmenopausal women (PmW) with osteoporosis (OP) demonstrated that sequential treatment with abaloparatide (ABL) followed by alendronate (ALN) resulted in lower…
  • Abstract Number: 1424 • ACR Convergence 2022

    Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial

    Joanna KEDRA1, Lina El Houari1, Florence Tubach1, Benjamin granger1 and Bruno Fautrel2, 1Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, 2Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
  • Abstract Number: 1488 • ACR Convergence 2022

    Incremental Healthcare Resource Utilization and Costs of Herpes Zoster in Patients with Psoriatic Arthritis: A Retrospective Cohort Study

    David Singer1, Philippe Thompson-Leduc2, Siyu Ma3, Deepshekhar Gupta4, Wendy Cheng5, Selvam Sendhil6, Manasvi Sundar6, Ella Hagopian5, Mei Sheng Duh7 and Sara Poston1, 1GSK, Philadelphia, PA, 2Analysis Group, Inc., Montréal, QC, Canada, 3GSK/Tufts Medical Center, Boston, MA, 4Analysis Group, Inc., Menlo Park, CA, 5Analysis Group, Inc., Boston, MA, 6Analysis Group, Inc., Los Angeles, CA, 7Analysis Group Inc, Boston, MA

    Background/Purpose: Patients with psoriatic arthritis (PsA) may be at increased risk of herpes zoster (HZ). HZ can involve a painful dermatomal rash and lead to…
  • Abstract Number: 2006 • ACR Convergence 2022

    Healthcare Resource Utilization and Economic Burden of Patients with Adequate and Inadequate Responses to Advanced Therapies for Rheumatoid Arthritis in Japan

    Kei Ikeda1, Yuko Kaneko2, Jayeshkumar Patel3, Toru Yamazaki4, Siran Fang3, Tsujita Yuki4 and Yutaka Kawahito5, 1Chiba University Hospital, Chiba, Japan, 2Keio University School of Medicine, Tokyo, Japan, 3AbbVie, Inc., North Chicago, IL, 4AbbVie GK, Tokyo, Japan, 5Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, Kyoto, Kyoto, Japan

    Background/Purpose: Substantial numbers of patients with RA receiving advanced therapies including biologics, biosimilars, and Janus kinase inhibitors do not achieve ACR50 responses and lack of…
  • Abstract Number: 2086 • ACR Convergence 2022

    Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus

    Ann E Clarke1, Manuel Ugarte-Gil2, Megan Barber3, John Hanly4, Murray Urowitz5, Yvan St. Pierre6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Sasha Bernatsky6, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul R Fortin15, Dafna Gladman16, Ian N. Bruce17, Michelle Petri18, Ellen M. Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan Mackay25, Guillermo Ruiz-Irastorza26, S. Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane Kamen32, Anca Askanase33, Bernardo Pons-Estel34 and Graciela Alarcón35, 1University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada, 2Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, 3Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Division of Rheumatology, Queen Elizabeth II Health Sciences Center (Nova Scotia Rehabilitation Site) and Dalhousie University, Halifax, NS, Canada, 5University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 6Research Institute of the McGill University Health Centre, Montréal, QC, Canada, 7Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, Republic of Korea, 9Instituto Nacional de Ciencias Medicas y Nutricion SZ, Ciudad de México, Mexico, 10Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, 11Cedars-Sinai Medical Center, Los Angeles, CA, 12University College London, London, United Kingdom, 13Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - Université Laval, Québec, QC, Canada, 16Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, 17Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, 18Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 19SUNY Downstate Health Sciences University, Department of Medicine, Brooklyn, NY, 20Raleigh Neurology Associates, Chapel Hill, NC, 21Northwestern University Feinberg School of Medicine, Chicago, USA, Chicago, IL, 22Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, 23Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 24Amsterdam University Medical Centers, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Autoimmune Diseases Research Unit, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Barakaldo, Spain, 27Emory University, Atlanta, GA, 28Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istambul, Turkey, 29University of California San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 35The University of Alabama at Birmingham, Oakland

    Background/Purpose: Remission and low disease activity (LDA) are associated with decreased flares, damage, and mortality. However, little is known about the impact of disease activity…
  • Abstract Number: 0059 • ACR Convergence 2022

    Healthcare Resource Utilization and Costs of Management of Lupus Nephritis in Adult and Juvenile Patients with Systemic Lupus Erythematosus

    Kenneth Kalunian1, Janice Ma2, Konrad Pisarczyk2, Richard Leff3, Kiruthi Palaniswamy4 and Li Long4, 1University of California San Diego, La Jolla, CA, 2Maple Health Group, LLC, New York, NY, 3Kezar Life Sciences, South San Francisco, CA, 4Kezar Life Sciences, Inc., South San Francisco, CA

    Background/Purpose: Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus (SLE), which develops in about one-third of SLE patients within…
  • Abstract Number: 0067 • ACR Convergence 2022

    Cost Per Responder in RA Patients Failing First Line Treatment

    Manuel Cardozo, Pharmalab PHL, Huixquilucan, Mexico

    Background/Purpose: The Colombian healthcare system is under economic pressure like many other systems in the world. In that sense, treatment choice involves cost in addition…
  • Abstract Number: 0283 • ACR Convergence 2022

    The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)

    Nobuyuki Yajima1, Toshihiro Matsui2 and Shigeto Tohma3, 1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2NHO Sagamihara National Hospital, Kanagawa, Japan, 3National Hospital Organization Tokyo National Hospital, Dallas, TX

    Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…
  • Abstract Number: 0143 • ACR Convergence 2021

    Economic and Healthcare Resource Use Burden of Systemic Sclerosis

    Dinesh Khanna1, Dan Furst2, Justin Li3, Qian Meng4, Tamara Lesperance5, Kenyatta Peoples6, Farah Ali5, Brian LaMoreaux5 and Stephanie Taylor7, 1University of Michigan, Ann Arbor, MI, 2University of California Los Angeles, Los Angeles, CA, 3Trinity Partners, Waltham, MA, 4Trinity Life Sciences, Waltham, MA, 5Horizon Therapeutics plc, Deerfield, IL, 6Horizon Therapeutics plc, Lake Forest, IL, 7Horizon Therapeutics plc, Whitehouse Station, NJ

    Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
  • Abstract Number: 0239 • ACR Convergence 2021

    Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019

    Elaine Husni1, Steven Peterson2, Natalie Dennis3, Feifei Yang4, Iris Lin4, Yiting Wang5, Soumya Chakravarty6, Claire Fischer3, May Shawi7, Arthur Quenéchdu3 and Joseph Merola8, 1Cleveland Clinic, Cleveland, OH, 2Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, 3Amaris, Health Economics and Market Access, Paris, France, 4Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, 5Janssen R&D, LLC, Titusville, NJ, 6Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 7Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 8Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to…
  • Abstract Number: 0240 • ACR Convergence 2021

    Economic Burden of Fatigue Among Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019

    Joseph Merola1, Feifei Yang2, Natalie Dennis3, Steven Peterson4, Iris Lin2, Yiting Wang5, Soumya Chakravarty6, Arthur Quenéchdu3, May Shawi7, Claire Fischer3 and Elaine Husni8, 1Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 2Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, 3Amaris, Health Economics and Market Access, Paris, France, 4Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, 5Janssen R&D, LLC, Titusville, NJ, 6Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, 7Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, 8Cleveland Clinic, Cleveland, OH

    Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). The objectives of this study…
  • Abstract Number: 0357 • ACR Convergence 2021

    Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland

    Sinead Maguire1, Wilson Fiona2, Phil Gallagher3 and Finbar (Barry) O'Shea1, 1St James's Hospital, Dublin, Ireland, 2Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, 3St Vincent's Hospital, Dublin, Ireland

    Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis of the axial skeleton. Persistent disease activity can result in significant disability and affect ability to maintain…
  • Abstract Number: 0424 • ACR Convergence 2021

    Incremental Healthcare Costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) Compared to Asthma: Retrospective Analysis of Commercial Claims Data in the United States (US)

    Christopher Bell1, Juliana Meyers2 and Mayank Ajmera2, 1GlaxoSmithKline, Research Triangle Park, NC, 2RTI-Health Solutions, Research Triangle Park, NC

    Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA), formerly Churg-Strauss Syndrome, is a rare, complex multisystem disorder, characterized by vascular inflammation and multisystem organ damage. EGPA manifests…
  • Abstract Number: 0562 • ACR Convergence 2021

    Inpatient Epidemiology and Resource Utilization of Ankylosing Spondylitis: National Inpatient Sample 2018

    Patompong Ungprasert1, Thanat Chaikijurajai2, Karn Wijarnpreecha3 and Paul Kroner3, 1Cleveland Clinic, Cleveland Heights, OH, 2Cleveland Clinic, Cleveland, OH, 3Mayo Clinic Florida, Jacksonville, FL

    Background/Purpose: Little is known about inpatient epidemiology, economic burden and resource utilization of patients with ankylosing spondylitis (AS). The current study aims to describe those…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences